parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.10 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in retinal horizontal cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly protein handling	0.90

No case: the score is under the bar. Receipt 2738

receipt 2746: HECW1 in dopamine neurons, braak

power: full sample +0.09 (p 0.735, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.09 (p 0.722, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.754, n 18). could be the mix.
skeptic: leave-one-out range -0.03 to +0.23, sign flips 2; without severely affected donors +0.09 (p 0.735, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HECW1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 2745: HECW1 in oligodendrocytes, braak

power: full sample -0.18 (p 0.476, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.19 (p 0.455, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.33 (p 0.176, n 18). could be the mix.
skeptic: leave-one-out range -0.29 to -0.06, sign flips 0; without severely affected donors -0.18 (p 0.476, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for HECW1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts